❭ Research by medical division ❭ Cancer Medicine ❭ Institute for Cancer Research ❭ Dept. of Tumor Biology ❭ Translational Cancer Therapy [Flatmark] ❭ Major collaborators ❭

Major collaborators

Academic collaborations

PERIMMUNE

The Section of Cellular Therapy

Pathology Research Radiumhospitalet 

EuroPMP

 

Commercial collaborations

Nadeno

Node

Bayer

 

 

 

 

 
Scroll to top

Home Dept. of Tumor Biology Translational Cancer Therapy [Flatmark]

  • Group members
  • From bench to bedside
  • Interventional clinical trials
  • Target discovery in peritoneal surface malignancies
  • Locally advanced and recurrent rectal cancer
  • Experimental treatment
  • Publications
  • News
  • Major collaborators

Recent publications

Torgunrud A, Lund-Andersen C, Davidson B, Nitschke Marcussen IK, Larsen SG, Dagenborg V, Flatmark K (2025)
High prevalence of KRAS and GNAS mutations in pseudomyxoma peritonei underscores opportunities for targeted therapeutic strategies
Pleura Peritoneum, 11 (1), 11-18
DOI 10.1515/pp-2025-0034, PubMed 41868810

Ree AH, Bousquet PA, Visnovska T, Lüders T, Geisler BP, Wang S, Bordin DL, Nilsen HL, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Berg JP, Flatmark K, Meltzer S (2026)
Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer
Br J Cancer, 134 (8), 1176-1182
DOI 10.1038/s41416-026-03357-6, PubMed 41731117

Davidson B, Stričak LM, Holth A, Torgunrud A, Wohlschlaeger J, Tötsch M, Bassarova A (2026)
The specificity of HEG1 as mesothelioma marker depends on the differential diagnosis
Virchows Arch, 488 (3), 617-626
DOI 10.1007/s00428-026-04438-w, PubMed 41656400



More publications

Oslo University Hospital is a part of Southern and Eastern Norway Regional Health Authority.

Webmaster for research pages: Trond Olav Berg

Cookie policy

Accessibility statement (in Norwegian)